account_id none on file
legal_name NeuroSense Therapeutics Ltd.
ticker NRSN
cik 1875091
domain neurosense-tx.com
linkedin_company_url https://www.linkedin.com/company/neurosense-therapeutics/?trk=company_logo
entry_point_account_id none on file
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 13 executives 5 family 0
why_nownone on file
callsnone on file
filings
2025, but does not include business travel, relocation, professional and business association dues and expenses reimbursed to officers,
filing / Mar 31, 2026 / receipt
In December 2021, the Company entered into an office space lease agreement (which commenced on January 1, 2022). Monthly rent payments including utilities amount to approximately $ 7 thousand and indexed to Israeli consumer price index.
filing / Mar 31, 2026 / receipt
healthcare industry and elsewhere is cost containment. Third party payors decide which drugs they will pay for and establish reimbursement and co-payment levels.
filing / Mar 31, 2026 / receipt
2021, we entered into an agreement which provides us access to co-working spaces, including office space in Cambridge, Massachusetts.
filing / Mar 31, 2026 / receipt
Alon Ben-Noon | Chief Executive Officer, Director | 46
filing / Mar 31, 2026 / receipt
Or Eisenberg | Chief Financial Officer | 44
filing / Mar 31, 2026 / receipt
Dr. Ferenc Tracik | Chief Medical Officer | 62
filing / Mar 31, 2026 / receipt
Dr. Niva Russek-Blum | Chief Technology Officer | 50
filing / Mar 31, 2026 / receipt
Hagit Binder | Chief Operating Officer | 47
filing / Mar 31, 2026 / receipt
2025, but does not include business travel, relocation, professional and business association dues and expenses reimbursed to officers,
filing / Mar 31, 2026 / receipt
In December 2021, the Company entered into an office space lease agreement (which commenced on January 1, 2022). Monthly rent payments including utilities amount to approximately $ 7 thousand and indexed to Israeli consumer price index.
filing / Mar 31, 2026 / receipt
healthcare industry and elsewhere is cost containment. Third party payors decide which drugs they will pay for and establish reimbursement and co-payment levels.
filing / Mar 31, 2026 / receipt
executives
| Alon Ben-Noon | Chief Executive Officer, Director | - | receipt |
| Dr. Ferenc Tracik | Chief Medical Officer | - | receipt |
| Dr. Niva Russek-Blum | Chief Technology Officer | - | receipt |
| Hagit Binder | Chief Operating Officer | - | receipt |
| Or Eisenberg | Chief Financial Officer | receipt |
familynone on file
upcomingnone on file
changesnone on file
mcp_package_hint
slug neurosense-therapeutics-ltd
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$